XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations - (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue $ 3,000,000 $ 7,000 $ 3,996,000 $ 15,000
Operating expenses:        
Research and development 2,382,000 1,768,000 7,922,000 8,481,000
General and administrative 2,221,000 1,071,000 6,627,000 5,216,000
Total operating expenses 4,603,000 2,839,000 14,549,000 13,697,000
Operating loss (1,603,000) (2,832,000) (10,553,000) (13,682,000)
Other (expense) income (1,084,000)   1,814,000  
Other (expense) income – related party 1,328,000 814,000 611,000 (114,000)
Interest income     1,000 12,000
Interest expense (6,000) (235,000) (6,000) (625,000)
Loss before income taxes and noncontrolling interest (1,365,000) (2,253,000) (8,133,000) (14,409,000)
Income tax provision 100,000 0 115,000 0
Net loss before noncontrolling interest (1,465,000) (2,253,000) (8,248,000) (14,409,000)
Less: net loss attributable to noncontrolling interest (378,000) (720,000) (2,312,000) (4,784,000)
Net loss attributable to vTv Therapeutics Inc. (1,087,000) (1,533,000) (5,936,000) (9,625,000)
Net loss attributable to vTv Therapeutics Inc. common shareholders $ (1,087,000) $ (1,533,000) $ (5,936,000) $ (9,625,000)
Class A Common Stock [Member]        
Operating expenses:        
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted $ (0.02) $ (0.03) $ (0.10) $ (0.21)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted 61,073,280 48,238,285 58,737,170 45,796,298